WCN26-5829 EFFICACY AND SAFETY OF FINERENONE AND EMPAGLIFLOZIN IN PATIENTS WITH INITIAL DECLINE IN ESTIMATED GLOMERULAR FILTRATION RATE: A CONFIDENCE TRIAL PRESPECIFIED ANALYSIS

Serious adverse events were reported in 8.5%, 10.5%, and 3.8%, respectively.TEAEs leading to treatment discontinuation occurred in 0.9%, 3.8%, and 1.0%.The incidence of steroid-specific side effects (e.g., moon face, buffalo hump) was low and generally mild.No deaths were reported. Conclusion:Nine months of treatment with targeted-release HR19042 capsules produced a clinically meaningful reduction in proteinuria and slowed eGFR decline compared with placebo, indicating a potential disease-modifying effect in patients with IgA nephropathy.HR19042 was generally well tolerated, with a safety profile consistent with locally acting oral budesonide.I have potential conflict of interest to disclose.Rong Huang and Su Zhang report being employed by Jiangsu Hengrui Pharmaceuticals.

Authors

Institutions

Publication Details

Journal
Kidney International Reports
Published
2026-05-01
DOI
https://doi.org/10.1016/j.ekir.2026.106507
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

WCN26-5829 EFFICACY AND SAFETY OF FINERENONE AND EMPAGLIFLOZIN IN PATIENTS WITH INITIAL DECLINE IN ESTIMATED GLOMERULAR FILTRATION RATE: A CONFIDENCE TRIAL PRESPECIFIED ANALYSIS

Amy K. Mottl, Mario Berger, Julio Rosenstock, Janet B. McGill et al.
Kidney International Reports
Renal Diseases and Glomerulopathies
article

WCN26-5829 EFFICACY AND SAFETY OF FINERENONE AND EMPAGLIFLOZIN IN PATIENTS WITH INITIAL DECLINE IN ESTIMATED GLOMERULAR FILTRATION RATE: A CONFIDENCE TRIAL PRESPECIFIED ANALYSIS

Amy K. Mottl, Mario Berger, Julio Rosenstock, Janet B. McGill, J B Green, Na Li, Meike Brinker, P Rossing, Muthiah Vaduganathan, Hiddo J.L. Heerspink, Rajiv Agarwal, Jose Luis Gorriz, Masaomi Nangaku, Johannes F.E. Mann, Charlie Scott
article en

Abstract

Serious adverse events were reported in 8.5%, 10.5%, and 3.8%, respectively.TEAEs leading to treatment discontinuation occurred in 0.9%, 3.8%, and 1.0%.The incidence of steroid-specific side effects (e.g., moon face, buffalo hump) was low and generally mild.No deaths were reported. Conclusion:Nine months of treatment with targeted-release HR19042 capsules produced a clinically meaningful reduction in proteinuria and slowed eGFR decline compared with placebo, indicating a potential disease-modifying effect in patients with IgA nephropathy.HR19042 was generally well tolerated, with a safety profile consistent with locally acting oral budesonide.I have potential conflict of interest to disclose.Rong Huang and Su Zhang report being employed by Jiangsu Hengrui Pharmaceuticals.

Kidney International ReportsVol. 11(5)
University of North Carolina at Chapel Hill (US), Brigham and Women's Hospital (US), University Medical Center Groningen (NL), Steno Diabetes Centers (DK), Harvard University (US), Bayer (United States) (US), Duke University (US), Washington University in St. Louis (US), Clinical Research Institute (US), Hospital Clínico Universitario de Valencia (ES), Katholische Stiftungshochschule München (DE), Richard L. Roudebush VA Medical Center (US), Dallas Diabetes Research Center (US), INCLIVA Health Research Institute (ES), Indiana University – Purdue University Indianapolis (US), Bayer (Germany) (DE), The University of Tokyo (JP)
Good health and well-being
Openalex Percentile: Top 8%
Renal Diseases and Glomerulopathies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.